Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial
by Traci Bratton
Shin J. Oh, MD, Distinguished Professor Emeritus of Neurology, University of Alabama at Birmingham, School of Medicine, stated, "I am extremely pleased to see the results from the first ever Phase 3 controlled study in this LEMS patient population, which confirmed a positive treatment effect for Firdapse. When combined with the favorable safety profile, the results indicate that the drug should become the standard of care in treating LEMS patients once approved by the FDA."